Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): K13
Therapeutic Area: Cardiology/Vascular Diseases Product Name: K13
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Yabao Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 15, 2015
Details:
Yabao receives exclusive rights to develop and commercialize innovative products targeting PTEN nuclear translocation for the treatment of stroke in China, Taiwan and Hong Kong while Primary Peptides retains rights in all other markets.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
